Effectiveness of Sacubitril/Valsartan: A Literature Review

• Autores: Zuñiga Olivera , Consuelo Hibon, Gonza-Escobar , Karol-Diana, Huamansupa-Quispealaya , Antoni, Huamansupa-Quispealaya , Dayana, Méndez-Veliz, Marleni, Mendoza Huarocc , Lucy-Karina
• Formato: artículo
• Fecha de Publicación: 2025
• Institución: Universidad Privada de Huancayo Franklin Roosevelt
• Repositorio: Visionarios en ciencia y tecnología
• Lenguaje: español
• OAI Identifier: oai:revistas.uroosevelt.edu.pe:article/153
• Enlace del recurso: https://revistas.uroosevelt.edu.pe/index.php/VISCT/article/view/153
• Nivel de acceso: acceso abierto

High blood pressure is a common and silent chronic disease that increases the risk of cardiovascular, renal, and cerebral complications. It affects millions of people worldwide, many without diagnosis or adequate treatment. Its control represents a major public health challenge, especially in developing countries.  Objective: To analyze the literature associated with the use of antihypertensives such as sacubitril/valsartan and their effectiveness, highlighting their importance in public health. Material and Methods: The PRISMA methodology was applied, initially identifying 326 articles, of which 298 were excluded from the analysis because they were review articles and not case reports. Next, 15 open-access full-text articles were selected, 9 of which were directly related to our research objective. In this article, we included only original clinical trials published between 2021 and 2024 in English and Spanish from the PubMed database. To find these publications, we used keywords such as sacubitril/valsartan, effectiveness, heart failure, cardiovascular. Results: Sacubitril/valsartan demonstrated increased therapeutic effectiveness. Similarly, some articles presented evidence of adverse reactions such as symptomatic hypotension, hyperkalemia, worsening renal function, dizziness, and angioedema. Conclusions: Based on the analyzed articles, it is concluded that sacubitril/valsartan therapy is effective, safe, and moderately tolerated. It can be considered a first-line treatment for various cardiovascular conditions, including heart failure, elevated natriuretic peptide levels, ventricular remodeling, blood pressure reduction, and heart failure with preserved ejection fraction, among others.